What Biotica Technology does

Isomerase is a Cambridge, United Kingdom-based synthetic biology contract research organization (CRO) that delivers end-to-end microbial bioproduction services to pharmaceutical, biotechnology, agritech, consumer goods, chemical manufacturing, food and ingredients, and functional materials companies. The firm operates a B2B services model with four named revenue streams — Fee-For-Service (FFS), Full-Time Equivalent (FTE), Consultancy, and Material Supply — and engages clients across both large multinationals (Regeneron, Roche, Syngenta, Croda, Pharmaron, Zymergen) and smaller biotech and agritech ventures. Its GTM motion is sales-led and direct, with quote-based engagements and no disclosed public pricing.

The company's core technology stack is built around four interconnected proprietary platforms: IsoZym, the end-to-end bioproduction platform spanning discovery through scale-up; EvoSelect, a machine learning platform for enzyme engineering and applied biocatalysis; IsoChassis, a suite of industrial microbial expression hosts; and Proteosynth, a cell-free protein synthesis platform for rapid screening of enzymes, proteins, and peptides. Underlying capabilities span bioinformatics, enzyme discovery and engineering, analog generation, strain bioengineering, pathway engineering, upstream and downstream process development, tech transfer to partner CDMOs, analytical chemistry, assay development, and biocatalysis. This integrated capability set positions Isomerase to take client programs from initial biomolecule discovery through commercial-ready process development without clients needing to build in-house synthetic biology infrastructure.

Isomerase holds ISO 9001:2015 and ISO 27001:2022 certifications and an EcoVadis Gold Sustainability Rating (2026), indicating enterprise-grade quality, information security, and ESG posture. Headcount is reported at 11–50 employees and revenue is not publicly disclosed; the only recorded equity funding round is a $5M raise in 2003 from Biotechnology Value Fund and Nordic Biotech. The company presents itself as an innovation partner for harnessing microbes to create therapeutics, enzymes, and consumer products sustainably, cost-effectively, and at scale, with technology transfer to partner CDMOs as the route to commercial manufacturing.

Name

Biotica Technology

Legal name

Isomerase

Website

https://isomerase.co

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Cambridge, UK-based synthetic biology CRO delivering end-to-end microbial bioproduction services across pharma, biotech, agritech, consumer goods, chemicals, food, and materials via proprietary platforms (IsoZym, EvoSelect, IsoChassis, Proteosynth).

Ownership category

akta.pro rank

Product category

Synthetic Biology Contract Research and Bioproduction Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• Microbial bioproduction services
• Synthetic biology platform
• Enzyme engineering services
• Bioprocess development
• Strain engineering services

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Fee-For-Service (FFS): Project-based service engagements where clients pay for specific deliverables and achievements of development goals.
2. Full-Time Equivalent (FTE) Services: Dedicated research team resources provided to complement client research operations on an ongoing basis.
3. Consultancy Services: Expert advisory and consulting engagements for synthetic biology, strain engineering, and bioprocess development.
4. Material Supply: Supply of proprietary compounds, microbial strains, enzymes, and other biological materials to clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Biotica Technology, operating via Isomerase, is a contract research and bioproduction organization that combines bioinformatics, enzyme discovery, strain engineering, pathway engineering, and upstream/downstream process development to discover and produce enzymes, proteins, peptides, natural products, small molecules, and microbial strains for pharmaceutical, agritech, consumer goods, chemical manufacturing, food and ingredients, and functional materials clients. The company delivers end-to-end services from discovery through technology transfer to partner CDMOs for commercial manufacturing.

Product overview

Isomerase is a biotechnology company offering an integrated platform of bioproduction solutions for harnessing microbes to create therapeutics, enzymes, and consumer products. The portfolio comprises four interconnected platforms: IsoZym® Bioproduction Platform (core end-to-end discovery and production), EvoSelect (ML-driven enzyme engineering), IsoChassis (microbial expression hosts), and Proteosynth (cell-free protein synthesis for rapid screening). These platforms work together to support the full development pipeline from biomolecule discovery through commercial-scale bioprocess development.

Differentiator

Problem solved

Functional benefit

Brands

• IsoZym: Bioproduction platform for discovery and production of enzymes, proteins, peptides, and natural products.
• EvoSelect
• IsoChassis
• Proteosynth

Products and services

• IsoZym Bioproduction Platform End-to-end bioproduction platform for discovery and production of enzymes, proteins, peptides, and natural products using microbial systems; supports the full development pipeline from biomolecule discovery through commercial-scale bioprocess development for enterprise clients in pharma, biotech, and related sectors.
• EvoSelect Machine learning platform for enzyme engineering that delivers ML-guided enzyme optimization and applied biocatalysis, enabling accelerated development cycles for therapeutic and industrial enzyme applications.
• IsoChassis Suite of industrial microbial expression hosts for protein expression and biomanufacturing, including proprietary and engineered strains such as Pichia for scalable biomolecule production.
• Proteosynth Cell-free protein synthesis platform for rapid screening of enzymes, proteins, and peptides, enabling fast characterization and ranking of candidates prior to microbial production.
• Fee-For-Service (FFS) Engagements Project-based contract research service where clients pay for specific deliverables and the achievement of defined development goals across the bioproduction pipeline.
• Full-Time Equivalent (FTE) Services Dedicated research team resources provided on an ongoing basis to complement client research operations across synthetic biology, strain engineering, and bioprocess development.
• Consultancy Services Expert advisory and consulting engagements on synthetic biology, strain engineering, and bioprocess development for enterprise clients evaluating or scaling bio-based manufacturing.
• Material Supply Supply of proprietary compounds, microbial strains, enzymes, and other biological materials to clients for use in their own research, screening, and process development programs.

Named customers16 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Emerging players

• EnginZyme: Swedish synthetic biology company offering enzyme engineering and biocatalytic process development services for chemicals and pharma — comparable in stage and capability breadth to Isomerase but with a narrower specialty chemicals focus.

Direct peers

• Codexis: Specialist enzyme engineering and biocatalysis company offering protein engineering, process development and CDMO services — directly comparable to Isomerase's EvoSelect and IsoZym platforms and similar buyer base in pharma and specialty chemicals.
• Conagen: Synthetic biology company providing strain engineering, fermentation and scale-up services for ingredients, flavors, fragrances and biologics — closely overlaps with Isomerase's microbial bioproduction, natural product and enzyme engineering capabilities.
• Bota Bio: Synthetic biology CDMO offering end-to-end strain engineering, fermentation process development and scale-up for therapeutics and consumer products — comparable scope and customer profile to Isomerase's integrated platform.
• C-LEcta: German biocatalysis and enzyme engineering company offering protein engineering, process development and CDMO services — directly comparable to Isomerase's EvoSelect enzyme engineering and IsoZym bioproduction offerings.

Broad incumbents

• Novonesis (Novozymes): Global industrial enzymes and microbial bioproduction leader serving food, agriculture and consumer goods — competes with Isomerase on biocatalysis and enzyme engineering but at a vastly larger scale and with its own product portfolio.
• Amyris: Synthetic biology company developing and producing sustainable ingredients via microbial fermentation — overlaps with Isomerase's consumer goods, food and specialty chemicals use cases but operates at much greater scale.
• Ginkgo Bioworks: Large-scale synthetic biology platform offering cell engineering, strain development and biomanufacturing services across pharma, food and industrial biotech — broader and better-capitalized than Isomerase but serving the same microbial-foundry buyer.

Regional players

• Touchlight Genetics: UK-based CDMO for enzymatic DNA and microbial bioprocessing — regional peer in the same Cambridge/UK biotech cluster with overlapping microbial manufacturing capability and similar pharma/biotech buyer base.
• bit.bio: Cambridge, UK-based synthetic biology company operating a cell-coding platform with bioprocess development capabilities — same Cambridge ecosystem as Isomerase and overlapping synthetic biology and biomanufacturing capability, though with a stem-cell focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/3137318

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotica Technology